PacBio Announces Strategic Collaboration with n-Lorem Foundation and EspeRare
PacBio announced plans to pursue a strategic collaboration with the n-Lorem Foundation and EspeRare that we believe will position long-read whole-genome sequencing as enabling infrastructure to support the development of individualized antisense oligonucleotide therapies for ultra-rare genetic diseases. Under the proposed collaboration, PacBio will provide its scientific expertise, and the collaboration will utilize PacBio's long-read whole genome sequencing technology, to study the design, feasibility assessment, and molecular characterization of ASO therapies - to help extend the role of long-read genomics for those who may lack effective treatment options. ASO therapies require a complete understanding of the genomic architecture, including variant phasing, structural variation, repeat expansions, and regulatory alterations that are frequently missed or unresolved by standard sequencing approaches. By integrating long-read whole-genome sequencing earlier in the therapeutic development process, the proposed collaboration will aim to reduce the need for multiple sequential tests, accelerate target validation, and improve confidence in ASO design. Under the proposed collaboration, PacBio will donate sequencing reagents and provide expert scientific resources to support long-read genome analysis for research to further development of therapeutic treatments for individuals with rare diseases. These efforts are intended to directly inform target identification, ASO design feasibility, and regulatory-grade molecular characterization, strengthening the end-to-end pipeline from genomic discovery to enabling development of therapeutic interventions.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on PACB
About PACB
About the author

Pacific Biosciences Announces Q4 and Full Year 2025 Financial Results Date
- Earnings Release Date: Pacific Biosciences will report its Q4 and full-year 2025 financial results on February 12, 2026, at 5:00 PM ET, demonstrating the company's commitment to transparency and investor communication.
- Revenue Growth: Preliminary fourth-quarter revenue is expected to reach approximately $44.6 million, reflecting a 14% year-over-year increase, while full-year revenue is projected at $160 million, a 4% rise from the previous year, driven primarily by strong sales of the Vega sequencing platform.
- System Placement Trends: The deployment count for the Vega system surged to 42 units in Q4 2025 from just 7 units a year earlier, while the Revio system placements slightly declined to 21 units, indicating a market preference shift towards the Vega platform.
- Stock Performance: Over the past year, PACB's stock traded between $1.84 and $2.12, closing at $2.57 with a 1.98% increase, reflecting market confidence in the company's growth potential.

Pacific Biosciences (PACB) Reports 14% Q4 Revenue Growth for 2025
- Revenue Growth: Pacific Biosciences anticipates approximately $44.6 million in Q4 2025 revenue, up 14% from $39.2 million in the prior year, driven by strong sales of its Vega sequencing platform, indicating robust performance.
- Instrument and Consumables Revenue: Q4 2025 instrument revenue is expected to rise to $17.3 million from $15.3 million, while consumables revenue jumps from $18.8 million to $21.6 million, reflecting sustained market demand and operational efficiency.
- System Deployment Trends: The placement count for the Vega system surged to 42 units in Q4 2025 from 7 units year-over-year, while the Revio system placements declined from 23 to 21 units, highlighting a shift in market preference towards Vega amid challenges for Revio.
- Future Outlook: CEO Christian Henry noted that the SPRQ-Nx technology's cost reductions and enhanced multiomic capabilities are expected to catalyze growth in 2026 and beyond, demonstrating the company's confidence in future market opportunities.






